Skip Navigation
Menu
ACP Journal Club |19 July 2016

Adding candesartan-HCTZ to rosuvastatin increased adverse events but not benefits in patients at intermediate CV risk

Charles B. Eaton MD, MS

Article, Author, and Disclosure Information
FULL TEXT
Yusuf S, Lonn E, Pais P, et al. Blood-pressure and cholesterol lowering in persons without cardiovascular disease. N Engl J Med. 2016;374:2032-43. 27039945

GIM/FP/GP:

Cardiology:

In patients at intermediate cardiovascular (CV) risk, does rosuvastatin plus combination candesartan–hydrochlorothiazide (HCTZ) reduce major CV events?
Randomized, placebo-controlled, 2 x 2 factorial trial (Heart Outcomes Prevention Evaluation [HOPE]-3 trial). ClinicalTrials.gov NCT00468923.
Concealed.*
Blinded* (patients, clinicians, outcome assessors, and steering committee).
Median 5.6 years.
FULL TEXT
PDF
Not Available
Citations
Citation

Eaton MD CB. Adding candesartan-HCTZ to rosuvastatin increased adverse events but not benefits in patients at intermediate CV risk. Ann Intern Med. ;165:JC8. doi: 10.7326/ACPJC-2016-165-2-008

Download citation file:

© 2018

×
Permissions

Published: Ann Intern Med. 2016;165(2):JC8.

DOI: 10.7326/ACPJC-2016-165-2-008

©
2016 American College of Physicians
0 Citations

Related Articles
Combination candesartan–HCTZ did not reduce major CV events in patients at intermediate CV risk
Annals of Internal Medicine; 165 (2): JC7
Rosuvastatin reduced major cardiovascular events in patients at intermediate cardiovascular risk
Annals of Internal Medicine; 165 (2): JC6
Benazepril plus amlodipine reduced cardiovascular risk more than benazepril plus hydrochlorothiazide
Annals of Internal Medicine; 150 (10): JC5-8
Update in Cardiology
Annals of Internal Medicine; 141 (8): 628-634
View MoreView Less

Journal Club
Combination candesartan–HCTZ did not reduce major CV events in patients at intermediate CV risk
Annals of Internal Medicine; 165 (2): JC7
Rosuvastatin reduced major cardiovascular events in patients at intermediate cardiovascular risk
Annals of Internal Medicine; 165 (2): JC6
Benazepril plus amlodipine reduced cardiovascular risk more than benazepril plus hydrochlorothiazide
Annals of Internal Medicine; 150 (10): JC5-8
In patients with SBP ≥ 130 mm Hg and CV risk, intensive vs standard BP control reduced CV events and mortality
Annals of Internal Medicine; 164 (4): JC15
View MoreView Less

Related Topics
Cardiology
Coronary Risk Factors
Dyslipidemia
Hypertension
Nephrology

Cardiology, Coronary Risk Factors, Dyslipidemia, Hypertension, Nephrology.

PubMed Articles
Inhibition of SRC/FAK cue: A novel pathway for the synergistic effect of rosuvastatin on the anti-cancer effect of dasatinib in hepatocellular carcinoma.
Life Sci 2018.
A randomized, double-blind, placebo-controlled phase 3 trial of oral brincidofovir for cytomegalovirus prophylaxis in allogeneic hematopoietic-cell transplantation.
Biol Blood Marrow Transplant 2018.
View More

Results provided by: PubMed

CONTINUE WITH LIMITED ACCESS
Annals of Internal Medicine
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
acp link acp
silverchair link silverchair

Copyright © 2018 American College of Physicians. All Rights Reserved.

Print ISSN: 0003-4819 | Online ISSN: 1539-3704

Privacy Policy

|

Conditions of Use

This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy. | Accept
×

You need a subscription to this content to use this feature.

×
PDF Downloads Require Access to the Full Article.
Annals of Internal Medicine
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
Access to this Free Content Requires Users to be Registered and Logged In. Please Choose One of the Following Options
Annals of Internal Medicine
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×